Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Cancer Gene Ther. 2009 Sep 18;17(2):86–96. doi: 10.1038/cgt.2009.60

Figure 6. Bystander xenograft tumor model of SR39 and MGMK/SR39.

Figure 6

Pools of rat C6 glioma cells transfected with pUB were mixed with cells stably transfected with pUB:HSVTK (□), pUB:mgmk/HSVTK (■), pUB:SR39 (◇) and pUB:mgmk/SR39 (◆) were used to seed tumors in nude mice (n=5 for each group). When tumor size reached 3-4mm (day 0), (A) GCV (1mg/kg) or (B) PBS was administered twice a day for 8 days. During this period, tumor growth was measured every other day. Tumor volume was calculated using the formula 4/3π ((Width × Length × Height)/2), plotted and analyzed for statistical significance using Student's t-test. Asterisks denote statistical significance (P ≤ 0.05) in tumor sizes between mice harboring 5% of MGMK/SR39-expressing tumor cells and those that received 5% of either HSVTK-, MGMK/HSVTK-, or SR39-expressing tumor cells in the presence of 1mg/kg GCV.